Lantern Pharma Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Lantern Pharma Inc. (LTRN) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $22.41 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-08-14
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-12-31 was $119.00, a 82.98% decline year-over-year.
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-09-30 was -$345.00, a 127.00% decline year-over-year.
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-06-30 was $12.27K, a 53.00% increase year-over-year.
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-03-31 was $10.37K.
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $22.41K, a 147.19% increase from fiscal 2024.
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $9.06K.
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was -$115.84K.
- Lantern Pharma Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was -$128.92K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $119.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$226.00 derived: sum of 2 quarters · filed 2026-03-30 | $12.04K derived: sum of 3 quarters · filed 2026-08-14 | $22.41K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$345.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $11.92K derived: sum of 2 quarters · filed 2026-08-14 | $22.29K 10-Q · filed 2025-11-12 | $22.99K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $12.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $22.63K 10-Q · filed 2026-08-14 | $23.33K derived: sum of 3 quarters · filed 2026-08-14 | $24.61K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $10.37K 10-Q · filed 2026-05-15 | $11.07K derived: sum of 2 quarters · filed 2026-05-15 | $12.35K derived: sum of 3 quarters · filed 2026-05-15 | $20.36K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $699.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.98K derived: sum of 2 quarters · filed 2026-03-30 | $9.99K derived: sum of 3 quarters · filed 2026-03-30 | $9.06K 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $9.29K derived: sum of 2 quarters · filed 2025-11-12 | $8.37K 10-Q · filed 2025-11-12 | -$30.65K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $8.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $7.09K 10-Q · filed 2025-08-13 | -$31.93K derived: sum of 3 quarters · filed 2025-08-13 | -$47.84K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$929.00 10-Q · filed 2025-05-15 | -$39.95K derived: sum of 2 quarters · filed 2025-05-15 | -$55.86K derived: sum of 3 quarters · filed 2025-05-15 | -$78.81K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$39.02K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$54.93K derived: sum of 2 quarters · filed 2025-03-27 | -$77.88K derived: sum of 3 quarters · filed 2025-03-27 | -$115.84K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$15.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$38.86K derived: sum of 2 quarters · filed 2024-11-07 | -$76.82K 10-Q · filed 2024-11-07 | -$129.42K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$22.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$60.91K 10-Q · filed 2024-08-08 | -$113.50K derived: sum of 3 quarters · filed 2024-08-08 | -$141.14K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$37.96K 10-Q · filed 2024-05-09 | -$90.56K derived: sum of 2 quarters · filed 2024-05-09 | -$118.19K derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$52.60K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$80.23K derived: sum of 2 quarters · filed 2024-03-18 | -$128.92K 10-K · filed 2024-03-18 | |
| 2022-09-30 | -$27.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$76.33K 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | -$48.69K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |